Targeted therapy combined with radiotherapy in non-small-cell lung cancer: a review of the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society)
Clin. transl. oncol. (Print)
; 19(1): 31-43, ene. 2017. tab
Article
in English
| IBECS
| ID: ibc-159116
Responsible library:
ES1.1
Localization: BNCS
ABSTRACT
In recent years, major advances in our understanding of the molecular biology of lung cancer, together with significant improvements in radiotherapy technologies, have revolutionized the treatment of non-small cell lung cancer (NSCLC). This has led to the development of new therapies that target molecular mutations specific to each tumor type, acting on the cell surface antigens or intracellular signaling pathways, or directly affecting cell survival. At the same time, ablative dose radiotherapy can be delivered safely in the context of metastatic disease. In this article, the GOECP/SEOR (Oncological Group for Study of Lung Cancer/Spanish Society of Radiation Oncology) reviews the role of new targeted therapies used in combination with radiotherapy in patients with locally advanced (stage III) NSCLC and in patients with advanced, metastatic (stage IV) NSCLC (AU)
RESUMEN
No disponible
Search on Google
Collection:
National databases
/
Spain
Database:
IBECS
Main subject:
Radiotherapy
/
Combined Modality Therapy
/
Carcinoma, Non-Small-Cell Lung
/
Antibodies, Monoclonal
/
Neoplasm Metastasis
Limits:
Female
/
Humans
/
Male
Language:
English
Journal:
Clin. transl. oncol. (Print)
Year:
2017
Document type:
Article
Institution/Affiliation country:
Hospital Ruber Internacional/Spain
/
Hospital Universitario Fundación Jiménez Díaz/Spain
/
Hospital Universitario La Ribera/Spain
/
Hospital Universitario Puerta del Mar/Spain
/
Hospital Universitario Quirón/Spain
/
Hospital Universitario Santiago de Compostela/Spain
/
Hospital de la Esperanza/Spain